Savene

RSS

dexrazoxane

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Savene. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Savene.

This EPAR was last updated on 08/10/2019

Authorisation details

Product details
Name
Savene
Agency product number
EMEA/H/C/000682
Active substance
dexrazoxane hydrochloride
International non-proprietary name (INN) or common name
dexrazoxane
Therapeutic area (MeSH)
Extravasation of Diagnostic and Therapeutic Materials
Anatomical therapeutic chemical (ATC) code
V03AF02
Publication details
Marketing-authorisation holder
Clinigen Healthcare B.V.
Revision
14
Date of issue of marketing authorisation valid throughout the European Union
27/07/2006
Contact address

Schiphol Boulevard 359
WTC Schiphol Airport
D Tower 11th floor
1118BJ Schiphol
The Netherlands

Product information

11/01/2019 Savene - EMEA/H/C/000682 - T/0038

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

ALL OTHER THERAPEUTIC PRODUCTS

Therapeutic indication

Savene is indicated for the treatment of anthracycline extravasation.

Assessment history

How useful was this page?

Add your rating